Revealing the secret behind Epstein-Barr virus-specific tumor immune contexture

Chu-Xia Deng

doi:10.1002/cac2.12529

Cancer Communications ›› 2024, Vol. 44 ›› Issue (4) :491 -494. DOI: 10.1002/cac2.12529

RESEARCH HIGHLIGHTS

Revealing the secret behind Epstein-Barr virus-specific tumor immune contexture

Chu-Xia Deng ¹^,²^,³^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Chu-Xia Deng. Revealing the secret behind Epstein-Barr virus-specific tumor immune contexture. Cancer Communications, 2024, 44(4): 491-494 DOI:10.1002/cac2.12529

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186(8):1652–1669.

[2]	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249.

[3]	Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264–279.

[4]	Qiu MZ, He CY, Yang DJ, Zhou DL, Zhao BW, Wang XJ, et al. Observational cohort study of clinical outcome in Epstein-Barr virus associated gastric cancer patients. Ther Adv Med Oncol. 2020;12:1758835920937434.

[5]	Zavros Y, Merchant JL. The immune microenvironment in gastric adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2022;19(7):451–467.

[6]	Kim TS, da SE, Coit DG, Tang LH. Intratumoral Immune Response to Gastric Cancer Varies by Molecular and Histologic Subtype. Am J Surg Pathol. 2019;43(6):851–860.

[7]	Qiu MZ, Wang C, Wu Z, Zhao Q, Zhao Z, Huang CY, et al. Dynamic single-cell mapping unveils Epstein‒Barr virus-imprinted T-cell exhaustion and on-treatment response. Signal Transduct Target Ther. 2023;8(1):370.

[8]	He L, Deng C. Recent advances in organotypic tissue slice cultures for anticancer drug development. Int J Biol Sci. 2022;18(15):5885–5896.

[9]	Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, et al. Organoid Modeling of the Tumor Immune Microenvironment. Cell. 2018;175(7):1972–1988.e16.

[10]	Voabil P, de Bruijn M, Roelofsen LM, Hendriks SH, Brokamp S, van den Braber M, et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat Med. 2021;27(7):1250–1261.

[11]	Chakrabarty S, Quiros-Solano WF, Kuijten MMP, Haspels B, Mallya S, Lo CSY, et al. A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture. Cancer Res. 2022;82(3):510–520.

[12]	Xing F, Liu YC, Huang S, Lyu X, Su SM, Chan UI, et al. Accelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform. Theranostics. 2021;11(19):9415–9430.